Russell Investments Group Ltd. Has $4.95 Million Holdings in Haemonetics Co. (NYSE:HAE)

Russell Investments Group Ltd. lessened its holdings in Haemonetics Co. (NYSE:HAEGet Rating) by 3.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 78,346 shares of the medical instruments supplier’s stock after selling 3,146 shares during the period. Russell Investments Group Ltd. owned 0.15% of Haemonetics worth $4,951,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. State of Michigan Retirement System raised its holdings in Haemonetics by 1.7% in the 1st quarter. State of Michigan Retirement System now owns 12,974 shares of the medical instruments supplier’s stock worth $820,000 after acquiring an additional 218 shares during the period. Louisiana State Employees Retirement System raised its holdings in Haemonetics by 2.3% in the 1st quarter. Louisiana State Employees Retirement System now owns 13,400 shares of the medical instruments supplier’s stock worth $769,000 after acquiring an additional 300 shares during the period. HHM Wealth Advisors LLC bought a new position in Haemonetics in the 1st quarter worth $25,000. Eaton Vance Management raised its holdings in Haemonetics by 4.6% in the 4th quarter. Eaton Vance Management now owns 9,756 shares of the medical instruments supplier’s stock worth $435,000 after acquiring an additional 433 shares during the period. Finally, Nordea Investment Management AB raised its holdings in Haemonetics by 1.2% in the 1st quarter. Nordea Investment Management AB now owns 58,947 shares of the medical instruments supplier’s stock worth $3,681,000 after acquiring an additional 692 shares during the period. Institutional investors and hedge funds own 98.51% of the company’s stock.

Insider Buying and Selling at Haemonetics

In other news, CEO Christopher Simon sold 1,148 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $62.60, for a total transaction of $71,864.80. Following the transaction, the chief executive officer now directly owns 213,724 shares in the company, valued at $13,379,122.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Christopher Simon sold 1,148 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $62.60, for a total transaction of $71,864.80. Following the transaction, the chief executive officer now directly owns 213,724 shares in the company, valued at $13,379,122.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Josep Llorens sold 1,418 shares of the company’s stock in a transaction that occurred on Thursday, May 19th. The stock was sold at an average price of $59.10, for a total transaction of $83,803.80. Following the transaction, the executive vice president now owns 17,335 shares in the company, valued at $1,024,498.50. The disclosure for this sale can be found here. Insiders have sold a total of 8,095 shares of company stock worth $482,496 over the last ninety days. Corporate insiders own 1.65% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on HAE shares. StockNews.com upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Thursday, July 21st. Barrington Research boosted their price objective on shares of Haemonetics from $71.00 to $77.00 in a report on Wednesday, May 11th. Morgan Stanley boosted their price objective on shares of Haemonetics from $60.00 to $70.00 and gave the stock an “equal weight” rating in a report on Friday, July 1st. JMP Securities restated a “buy” rating and set a $80.00 price objective on shares of Haemonetics in a report on Friday, July 8th. Finally, Raymond James boosted their price objective on shares of Haemonetics from $63.00 to $76.00 and gave the stock an “outperform” rating in a report on Friday, July 1st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $72.40.

Haemonetics Stock Performance

NYSE HAE opened at $73.60 on Thursday. The stock has a market cap of $3.78 billion, a P/E ratio of 87.62 and a beta of 0.39. The company’s 50-day simple moving average is $65.59 and its 200 day simple moving average is $59.38. Haemonetics Co. has a twelve month low of $43.50 and a twelve month high of $77.08. The company has a quick ratio of 1.05, a current ratio of 1.71 and a debt-to-equity ratio of 0.75.

Haemonetics (NYSE:HAEGet Rating) last posted its earnings results on Tuesday, May 10th. The medical instruments supplier reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.05. The business had revenue of $265.00 million for the quarter, compared to analysts’ expectations of $257.11 million. Haemonetics had a net margin of 4.37% and a return on equity of 18.57%. The firm’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.46 earnings per share. As a group, research analysts forecast that Haemonetics Co. will post 2.72 earnings per share for the current fiscal year.

About Haemonetics

(Get Rating)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading



Receive News & Ratings for Haemonetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Haemonetics and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *